Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells ...

In 2024, Professor Sebastian Kobold's research group at LMU University Hospital had already shown that the metabolite ...

CAR T-cell therapy, considered one of the most promising breakthroughs in cancer treatment, works by harnessing the patient’s ...

CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...

Please provide your email address to receive an email when new articles are posted on . Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...